Rite Aid Corporation stock price

Rite Aid Corporation latest news:


  • 02/14/2018 06:44:04

    Criteo stock soars on strong results, outlook

    Shares of ad-tech company Criteo S.A. rose 24% in premarket trading Wednesday after the company reported better-than-expected financial results for the December quarter and delivered a strong outlook. Criteo's net income attributable to shareholders rose to $53 million or 78 cents per share, from $41 million or 60 cents a year ago. On an adjusted basis, net income grew to $82 million from $55 million. Earnings per share of $1.21 rose from 84 cents in the year-earlier period and came in ahead of analysts' expectations for 93 cents. Revenue excluding traffic-acquisition costs increased to $277 million from $225 million. The company said it expects first-quarter revenue to be between $230 million and $235 million, excluding traffic-acquisition costs, ahead of consensus expectations for $205 million. "I'm confident our expanding commerce marketing ecosystem positions us well for future growth in 2018 and beyond," CEO Eric Eichmann said on Criteo's earnings call. As of Tuesday's close, Criteo shares were down 49% over the past 12 months, after getting hammered late last year in response to changes Apple Inc. made to its privacy settings on the Safari mobile browser. The S&P 500 Index has gained 14% over the last year. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 02/09/2018 09:12:56

    Uber and Waymo reach settlement in trade-secrets suit

    Uber Technologies Inc. said Friday that it had settled its lawsuit with Alphabet Inc.'s Waymo that hinged on an alleged theft of trade secrets. "I want to express regret for the actions that have caused me to write this letter," said Uber CEO Dara Khosrowshahi in a statement. He added: "While we do not believe that any trade secrets made their way from Waymo to Uber, nor do we believe that Uber has used any of Waymo's proprietary information in its self-driving technology, we are taking steps with Waymo to ensure our Lidar and software represents just our good work." Waymo alleged that one of its former engineers, Anthony Levandowski, stole thousands of documents before leaving the company and founding his own self-driving start-up, which was acquired by Uber early on. In a statement, Waymo said that it had reached an agreement with Uber "to ensure that any Waymo confidential information is not being incorporated in Uber Advanced Technologies Group hardware and software," according to the Verge. Alphabet shares are up 2.2% in Friday trading and 24% over the past 12 months. The S&P 500 has gained 12% in that time.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 02/08/2018 14:24:35

    BRIEF-Rite Aid Announces Continued Progress In Sale Of Assets To Walgreens Boots Alliance

    Rite Aid Corp(RAD): * RITE AID ANNOUNCES CONTINUED PROGRESS IN SALE OF ASSETS TO WALGREENS BOOTS ALLIANCE.

  • 02/07/2018 14:23:09

    AIRSHOW-Airbus says A400M deal with buyers will limit future losses

    Airbus on Wednesday announced possible further writeoffs on its troubled A400M military transport, but said a new agreement with seven NATO buyers about revamping delivery schedules and contract terms would limit its future exposure.

  • 01/24/2018 12:31:02

    Rite Aid settles U.S. criminal probe into pseudoephedrine sales

    Jan 24 (Reuters) - Rite Aid Corp will pay $4 million to resolve a U.S. Department of Justice criminal probe into the improper sale of pseudoephedrine, an ingredient often used to make the stimulant methamphetamine, federal prosecutors said on Wednesday.

  • 01/22/2018 14:36:42

    BRIEF-Rite Aid Provides Update On Sale Of Assets To Walgreens Boots Alliance

    Rite Aid Corp(RAD): * RITE AID PROVIDES UPDATE ON SALE OF ASSETS TO WALGREENS BOOTS ALLIANCE. * Rite Aid Corp(RAD) - AS OF JANUARY 22, 2018, RITE AID HAS TRANSFERRED 625 STORES AND RELATED ASSETS TO WBA. * Rite Aid Corp (RAD) - ON TRACK TO COMPLETE TRANSFER OF STORES IN SPRING OF THIS YEAR.

  • 01/14/2018 12:09:21

    UPDATE 1-U.S. transport chief to unveil revised self-driving car guidelines

    DETROIT, Jan 14 (Reuters) - The Trump administration plans to unveil revised self-driving car guidelines this summer as the government works to rewrite regulations that pose legal barriers to robot vehicles, U.S. Transportation Secretary Elaine Chao said on Sunday.

  • 01/14/2018 11:30:15

    U.S. transit chief to unveil revised self-driving car guidelines

    The Trump administration plans to unveil revised self-driving car guidelines this summer as the government works to rewrite regulations that pose legal barriers to robot vehicles, U.S. Transportation Secretary Elaine Chao said on Sunday.

  • 01/04/2018 10:11:14

    Walgreens close to completing purchase of 1,900+ Rite Aid stores

    Walgreens is edging closer to completing its long-suffering deal to acquire a large chunk of rival Rite Aid's stores.        

  • 01/04/2018 09:30:20

    Rite Aid Whiffs Big on Q3 Revenues


  • 01/03/2018 16:19:32

    BRIEF-Rite Aid CFO- WE CONTINUE TO EXPECT REIMBURSEMENT RATE HEADWINDS

    Rite Aid(RAD): * COO- RAD WILL HAVE 2,569 STORES LOCATED PRIMARILY IN 8 KEY STATES, TO BE SERVED BY 6 DISTRIBUTION. * COO- WE HAVE BETTER PREDICTABILITY ON REIMBURSEMENT RATE AND ACCESS FOR THE COMING YEAR. * COO- OUR TOTAL MED D ENROLLMENT FOR THE 2018 PLAN YEAR HAS SURPASSED 500,000 LIVES.

  • 01/03/2018 08:40:57

    Netflix confirms sequel to blockbuster original film 'Bright'

    Netflix Inc. on Wednesday confirmed that it has ordered a sequel to it's Dec. 22 fantasy cop ride along original film "Bright." The sequel will again star Will Smith and Joel Edgerton, and David Ayer will write and direct it. Netflix said that "Bright," which was widely panned by critics and has a 28% Rotten Tomatoes score, was the company's highest viewed original film ever on the service in its first week, and one of the platform's biggest original productions (including sequels, series and additional seasons). The company also said "Bright" is the top movie on Netflix in every country the service is in, with more people overseas watching it than are watching it domestically. The film, costing a reported $90 million to produce, garnered 11 million viewers in its first three days, according to Nielsen measurements, which MarketWatch calculated would be equal to about a $95 million Friday-to-Sunday opening weekend at the box office. Netflix didn't provide a release date for the "Bright" sequel. Shares of Netflix have gained 59% in the trailing 12-month period, while the S&P 500 index is up 20% and the Dow Jones Industrial Average is up nearly 25%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 12/21/2017 09:07:03

    UPDATE: Biogen shares drop 3% on negative update for Alzheimer's disease drug

    Biogen Inc. shares dropped 3% in morning trade Thursday after the company put out a negative update for its Alzheimer's disease drug. An Independent Data Monitoring Committee's 12-month analysis found that the therapy, BAN2401, "did not meet the criteria for success" based on the trial's primary endpoint. The phase 2 trial will continue through 18 months as planned, with a final analysis at the end, which is expected in the second half of next year. Biogen and Eisai Co. have been partners on BAN2401 since 2014, an agreement that included another Alzheimer's disease drug, E2609, which is also still being developed. Last month, the companies expanded the agreement and, as part of it, eliminated milestone payments for BAN2401. BAN2401's phase 2 trial enrolled 856 patients with early Alzheimer's disease. The Independent Data Monitoring Committee's analysis, called a "Bayesian analysis," was used in the hope that "it would enable us to demonstrate clinical success faster than more traditional study designs," said Lynn Kramer, chief clinical and medical officer of the Eisai Neurology Business Group. The companies emphasized that 16 interim analyses that looked at potential for futility did not find it, and that the Bayesian analysis at 12 months found "success was judged at an 80% of higher probability of achieving a Clinically Significant Difference." Despite the company's Thursday share decline, EvercoreISI analyst Umer Raffat said that the trial wasn't well understood and it shouldn't affect company shares much. "Today, all we learned is that the efficacy delta is ~10%)," Raffat said. "Trial continues to mo 18. This is key." Biogen shares have risen nearly 3% over the last three months, compared with a 7.5% rise in the S&P 500 and a 10.6% rise in the Dow Jones Industrial Average .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 12/21/2017 06:24:15

    Biogen shares drop 4% on negative update for Alzheimer's disease drug

    Biogen Inc. shares dropped 4.1% in premarket trade Thursday after the company put out a negative update for its Alzheimer's disease drug. An Independent Data Monitoring Committee's 12-month analysis found that the therapy, BAN2401, "did not meet the criteria for success" based on the trial's primary endpoint. The phase 2 trial will continue through 18 months as planned, with a final analysis at the end, which is expected in the second half of next year. Biogen and Eisai Co. have been partners on BAN2401 since 2014, an agreement that included another Alzheimer's disease drug, E2609, which is still being developed. Last month, the companies expanded the agreement and, as part of it, eliminated milestone payments for BAN2401. BAN2401's phase 2 trial enrolled 856 patients with early Alzheimer's disease. The Independent Data Monitoring Committee's analysis, called a "Bayesian analysis," was used in the hope that "it would enable us to demonstrate clinical success faster than more traditional study designs," said Lynn Kramer, chief clinical and medical officer of the Eisai Neurology Business Group. The companies emphasized that 16 interim analyses that looked at potential for futility did not find it, and that the Bayesian analysis at 12 months found "success was judged at an 80% of higher probability of achieving a Clinically Significant Difference." Biogen shares have risen 6% over the last three months, compared with a 7% rise in the S&P 500 and a 10.6% rise in the Dow Jones Industrial Average .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 12/19/2017 09:15:40

    Spark to announce gene therapy price in January

    Spark Therapeutics(ONCE) will announce the price for its gene therapy for inherited blindness, Luxturna, which was approved on Tuesday by U.S. regulators, in early January, a Spark spokeswoman said by email. Luxturna is expected to be available late in the first quarter of 2018, she said.

  • 12/14/2017 06:21:07

    Criteo stock plunges on lowered outlook following Apple's iOS update

    Shares of ad-retargeting firm Criteo S.A. fell 12% in premarket trading Thursday after the company dramatically lowered its 2018 revenue forecast due to changes Apple Inc. made to its mobile operating system. Apple's new iOS 11.2 software "disables the solution that some companies in the advertising ecosystem, including Criteo, currently use to reach Safari users," according to a release from Criteo. The company projects this change to reduce 2018 revenue by 22%, excluding traffic acquisition costs, if the firm can't effectively work within the new iOS landscape. Management had previously projected a 9% to 13% "net negative impact." Criteo said that it had a new solution "under development" but also that "its effectiveness cannot be assessed at this early stage." Criteo shares are down 23% this year, while Apple's stock is up 49%. The S&P 500 Index has gained 19%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 12/13/2017 12:15:16

    Congress secures tax deal, Trump backs 21-percent corporate rate

    WASHINGTON (Reuters) - Congressional Republicans have reached a deal on final tax legislation, the U.S. Senate's top Republican tax writer said on Wednesday, with President Donald Trump saying he would back a sharply lowered corporate tax rate of 21 percent.

  • 12/13/2017 11:30:43

    Senate secures tax deal, Trump backs 21-percent corporate rate

    WASHINGTON (Reuters) - Congressional Republicans have reached a deal on final tax legislation, the top Senate Republican tax writer said on Wednesday, with President Donald Trump saying minutes later he would back a corporate tax rate of 21 percent.

  • 12/13/2017 10:51:50

    Republicans reach deal on final tax legislation

    WASHINGTON (Reuters) - Congressional Republicans have reached a deal on final tax legislation, the top Senate Republican tax writer said on Wednesday, an achievement that would clear the way for final votes in the Senate and House of Representatives next week.

  • 11/29/2017 08:21:45

    Rite Aid's stock rockets on heavy volume for a 2nd-straight day

    Shares of Rite Aid Corp. rocketed on heavy volume Wednesday for a second-straight session, after the drugstore chain said it had completed the "pilot closing" of its amended asset purchase deal with Walgreens Boots Alliance Inc. . The stock shot up 14% to a 2-month high. Volume hit 39 million shares, enough to make it the most active stock on major U.S. exchanges, and already about double the full-day average. On Tuesday, after the stock shot up 16% on volume of 51.5 million shares. Rite Aid said late Monday that the pilot closing resulted in the transfer of 97 stores and related assets to Walgreens. Under the amended agreement announced in September, Rite Aid will sell a total of 1,932 stores, three distribution centers and related inventory for $4.38 billion in cash. Rite Aid expects to use the bulk of the proceeds from the deal to repay debt. Despite the stock's surge this week, it was still down 73.9% year to date, while Walgreen shares have lost 11.5% and the S&P 500 has gained 17.4%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 11/27/2017 14:28:13

    BRIEF-‍Rite Aid Announces First Closings Of Asset Sale To Walgreens Boots Alliance​

    * ‍RITE AID ANNOUNCES FIRST CLOSINGS OF ASSET SALE TO WALGREENS BOOTS ALLIANCE​ Source text for Eikon: Further company coverage:

  • More trends:

    RLI Corp.RLI | RLJ Lodging TrustRLJ | Roadrunner Transportation SystemsRRTS | Robert Half International Inc.RHI | Rockwell AutomationROK | Rockwell CollinsCOL | Rogers CommunicationRCI | Rogers CorporationROG | RollinsROL | Roper TechnologiesROP |